Oramed Pharmaceuticals Long Term Debt

Oramed Pharmaceuticals (ORMP) currently reports a long-term debt of $490K as of March 2026. That compares with $120K in the prior-year period — up 310.8% year over year. Use the charts on this page to explore Oramed Pharmaceuticals's long-term debt history and peer comparisons.

Oramed Pharmaceuticals's long-term debt increased from $120K to $490K — a 310.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oramed Pharmaceuticals reported $490K in long-term debt as of March 2026. That compares with $120K in the prior-year period — up 310.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $490K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Oramed Pharmaceuticals, and consider following ORMP for alerts when major investors trade the stock.

Oramed Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $490K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ORMP with unrelated industries.